In Utero Tenofovir Exposure May Not Affect Infant Bones In Utero Tenofovir Exposure May Not Affect Infant Bones
A new pilot study suggests prenatal tenofovir exposure does not have a significant effect on infant bone mineral content (BMC) or bone mineral density (BMD).Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 14, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Transgender Hormonal Therapy Might Interfere with PrEP
(MedPage Today) -- 13% decrease in tenofovir availability; unclear whether it compromises protection (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 26, 2018 Category: Endocrinology Source Type: news
Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2018 Category: Drugs & Pharmacology Source Type: news
Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016
Among persons living with HBV worldwide, approximately 27 million (10.5%) were aware of their infection, including 4.5 million (16.7%) who were on treatment. In 2017, all but two low- and middle-income countries could legally procure generic entecavir or tenofovir, the medicines active against HBV infection. (Source: PHPartners.org)
Source: PHPartners.org - July 19, 2018 Category: International Medicine & Public Health Source Type: news
Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV
Zoledronic acid improves low bone mineral density (BMD) better than switching from tenofovir disoproxil fumarate (TDF) to another antiretroviral drug in adults with HIV, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) has approved Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide -... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 17, 2018 Category: Drugs & Pharmacology Source Type: news
Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV
Fixed-dose bictegravir-emtricitabine-tenofovir (Biktarvy) maintains virologic suppression in adults with HIV-1 who are switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens, according to results from two noninferiority trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2018 Category: Drugs & Pharmacology Source Type: news
ART With Tenofovir Backbone Not Linked to Worse Outcomes ART With Tenofovir Backbone Not Linked to Worse Outcomes
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
EMA Panel Recommends Once-Daily HIV-1 Treatment Biktarvy EMA Panel Recommends Once-Daily HIV-1 Treatment Biktarvy
EMA panel recommends marketing authorization for a once-daily HIV-1 combo containing bictegravir, emtricitabine, and tenofovir.International Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 27, 2018 Category: Internal Medicine Tags: HIV/AIDS News Alert Source Type: news
No Higher Risk for Adverse Birth Outcomes with 3-Drug HIV Tx (CME/CE)
(MedPage Today) -- Tenofovir, emtricitabine, and ritonavir-boosted lopinavir compared with other ART (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 25, 2018 Category: OBGYN Source Type: news
Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r
WEDNESDAY, April 25, 2018 -- For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2018 Category: Pharmaceuticals Source Type: news
HIV Drug, Tenofovir, Appears Safe During Pregnancy
WEDNESDAY, April 25, 2018 -- Drugs to prevent HIV-positive pregnant women from infecting their unborn babies appear safe and don ' t raise the risk for premature birth or infant death, new research indicates.
The U.S. scientists said their findings... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 25, 2018 Category: General Medicine Source Type: news
SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2018 Category: Drugs & Pharmacology Source Type: news
Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo and Cimduo
All ARV regimens are being offered at a significant discount to the price of competing... Biopharmaceuticals, HIV/AIDS, FDA, Product Launch Mylan, Symfi, efavirenz, lamivudine, tenofovir (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2018 Category: Pharmaceuticals Source Type: news
